Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
Completed
- Conditions
- Hepatic Cancer
- Interventions
- Procedure: transarterial chemoembolisation
- Registration Number
- NCT06245785
- Lead Sponsor
- Tang-Du Hospital
- Brief Summary
Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. Established practice guidelines for patients with HCC and impaired liver function are lacking. The treatment allocation in these populations is heterogeneous and remains controversial. This study compared the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in patients with HCC and impaired liver function.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2200
Inclusion Criteria
- patients with HCC who received conventional LR or TACE
Exclusion Criteria
- （1） presence of portal vein tumour thrombosis (PVTT), hepatic artery, biliary duct or inferior vena cava invasion
- （2） extrahepatic spread (EHS)
- （3） albumin-bilirubin grade 1 or 3
- （4） Eastern Cooperative Oncology Group Performance Status (ECOG-PS) >1
- （5） tumour number >3
- （6） other tumours or severe cardiac, cerebral, and renal insufficiency
- （7）ascites, hepatic encephalopathy, and jaundice
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description transarterial chemoembolisation transarterial chemoembolisation -
- Primary Outcome Measures
Name Time Method overall survival 5 year The overall survival rate at 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Xijing hospital
🇨🇳Xian, Shaanxi, China
Tangdu hospital
🇨🇳Xian, Shaanxi, China